Polymer-modified synthetic proteins

• US 7,118,737 B2
• Filed: 07/12/2001
• Issued: 10/10/2006
• Est. Priority Date: 09/08/2000
• Status: Expired due to Fees

• Current Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Wilken, Jill G., Botti, Paolo, Kent, Stephen B. H., Chen, Shiah-yun, Hunter, Christie L., Cressman, Sonya, Low, Donald W., Kochendoerfer, Gerd G., Bradburne, James A.
• Primary Examiner(s): RUSSEL, JEFFREY E
• Application Number:
  US10/332,385
• Publication Number:
  US 20040115774A1
• Time in Patent Office: 1,916 Days
• Field of Search: 424/85.1, 424/85.2, 424/85.4, 424/85.5, 424/85.6, 424/85.7, 514/2, 514/8, 514/12, 514/21, 530/350, 530/351, 530/395, 530/397, 530/399, 530/402, 530/408, 530/409, 530/410, 525/420, 525/432, 528/335, 528/338, 528/339, 528/340, 564/160
• US Class Current: 424/85.1
• CPC Class Codes: C07K 1/1077 by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
• CPC Class Codes: C07K 14/52 Cytokines; Lymphokines; Interferons
• CPC Class Codes: C12P 21/02 having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The present invention relates to methods and compositions for modifying peptides, polypeptides and proteins with polymers, especially glyco-mimetic polymers, so as to improve their biological activity or pharmacokinetic properties. The invention further provides methods and uses for such polymer-modified peptides, polypeptides and proteins. The invention is particularly suitable for use in the synthesis of polymer-modified synthetic bioactive proteins (FIG. 1D), and of pharmaceutical compositions that contain such proteins.

Claims

1. A composition comprising an isolated synthetic bioactive protein having the formula

Protein-h_kU_kPolymer-J*,

wherein Protein comprises a polypeptide chain of a ribosomally specified protein, said polypeptide chain comprising one or more non-overlapping peptide segments covalently bonded by one or more chemical ligation sites,

U is a residue of a unique functional group covalently bonded to a mutually reactive unique functional group of a side chain h of one or more internal amino acids of one or more of said non-overlapping peptide segments, where k is a discrete integer selected from 1 to 6,

Polymer is a substantially non-antigenic water-soluble polymer, and

J* is a pendant group having a net charge under physiological conditions selected from the group consisting of negative, neutral and positive, and

wherein the composition is uniform with respect to the attachment sites of the Polymer to the Protein;

and

wherein said synthetic bioactive protein comprises a monomer molecular weight of greater than 25,000 Daltons.

2. The composition of claim 1, wherein said polypeptide chain comprises one or more irregular amino acids.

3. The composition of claim 2, wherein said irregular amino acid has a side chain group other than that of one of the 20 genetically encoded amino acids.

4. The composition of claim 3, wherein said irregular amino acid is selected from the group consisting of a pseudo amino acid and a hydrophobic amino acid delivative.

5. The composition of claim 1, wherein said side chain h is a non-natural side chain.

6. The composition of claim 1, wherein one or more of substituents U, Polymer and J* are separated by a spacer or linker, so as to have the formula:

-U_k-sl-B-s2-Polymer-s3-J*

where s1, s2, and s3 are spacer or linker moieties that may be the same or different, and may be individually present or absent, and B is a branching core substituent having three or more arms that may be the same or different.

7. The composition of claim 6, wherein one arm of a B substituent is joined to a U substituent, and a second arm of said B substituent is joined to Polymer.

8. The composition of claim 6, wherein B comprises four or more arms.

9. The composition of claim 6, wherein at least one of said arms comprises a residue of a bond selected from the group consisting of oxime, amide, amine, urethane, thioether, ester, thioester, hydrazide, oxazolidine, and thiazolidine.

10. The composition of claim 6, wherein B comprises a branching core selected from the group consisting of amino, carboxylate and mixed amino-carboxylate.

11. The composition of claim 10, wherein said amino branching core comprises lysine, said carboxylate branching core comprises glutamic or aspartic acid, and said mixed amino-carboxylate branching core comprises gamma-glutamic acid.

12. The composition of claim 6, wherein B-s2-Polymer-s3-J* comprises a molecular weight of between 1,500 and 80,000 Daltons.

13. The composition of claim 6, wherein side chain h is 2 or more, and wherein one or more of B-s2-Polymer-s3-J* is different.

14. The composition of claim 6, wherein B-s2-Polymer-s3-J* comprises a net charge under physiological conditions that is selected from the group consisting of negative, neutral and positive.

15. The composition of claim 6, wherein B-s2-Polymer-s3-J* is mono-disperse.

16. The composition of claim 1, wherein Polymer is a polyamide of the formula —

[C(O)—

X—

C(O)NH—

Y—

NH]_z or —

[NH—

Y—

NH—

C(O)—

X—

C(O)]_z—

, where X and Y are divalent radicals that may be the same or different and may be branched or linear, and z is an integer from 2 to 100, and where either or both of X and Y comprises a water-soluble repeat unit that may be linear or branched.

17. The composition of claim 16, wherein said X is a divalent radical of the formula —

NH—

X′

—

or —

X′

—

NH—

, where X′

is a divalent radical comprising a water-soluble repeat unit that may be linear or branched.

18. The composition of claim 16, wherein said Y is a divalent radical of the formula —

CO—

Y′

—

or —

Y′

—

CO—

, where Y′

is a divalent radical.

19. The composition of claim 16, wherein z is a discrete integer from 2 to 50.

20. The composition of claim 16, wherein said water-soluble repeat unit comprises an ethylene oxide repeat unit of the formula

—

(CH₂—

CH₂—

O)—

or —

(O—

CH₂—

CH₂)—

.

21. The composition of claim 20, wherein said ethylene oxide repeat unit has the formula

—

(CH₂CH₂—

O)_m—

or —

(O—

CH₂CH₂)_m—

,

where m is a discrete integer from 2 to 50.

22. The composition of claim 1, wherein J* is an ionizable group having a net charge under physiological conditions selected from the group consisting of negative and positive.

23. The composition of claim 22, wherein said ionizable group is selected from carboxyl, amine, and hydroxyl.

24. The composition of claim 16, having an increased circulating half-life in a mammal compared to a corresponding synthetic bioactive protein that is devoid of said water-soluble polymer.

25. A composition comprising a synthetic bioactive protein comprising a polypeptide chain comprising an amino acid sequence of a ribosomally specified glycoprotein, said polypeptide chain having one or more water-soluble polymers attached thereto and a monomer polypeptide molecular weight of greater than 25 kDa, wherein the composition is uniform with regard to the amino acid attachment sites of the polymer, and wherein the polymer is attached to at least one internal amino acid of the protein.

26. The composition of claim 25, wherein said synthetic bioactive protein possesses a bioactivity that mimics a bioactivity associated with said ribosomally specified glycoprotein.

27. The composition of claim 26, wherein said ribosomally specified glycoprotein is a cytokine.

29. The composition of claim 25, wherein said ribosomally specified glycoprotein comprises one or more glycosylation sites.

30. The composition of claim 29, wherein said water-soluble polymer is attached to said polypeptide chain at one or more sites corresponding to said one or more glycosylation sites.

31. The composition of claim 30, wherein said water-soluble polymer is attached to said polypeptide chain exclusively at one or more sites corresponding to said one or more glycosylation sites.

32. The composition of claim 25, wherein said ribosomally specified glycoprotein is a recombinantly produced glycoprotein.

33. The composition of claim 32, wherein said recombinantly produced glycoprotein is a non-natural glycoprotein.

34. The composition of claim 33, wherein said non-natural glycoprotein has one or more non-natural glycosylation sites.

35. The composition of claim 25, wherein said polypeptide chain comprises one or more irregular amino acids.

36. The composition of claim 25, wherein said water-soluble polymer comprises a molecular weight of between 1,500 and 80,000 Daltons.

37. The composition of claim 25, wherein said water-soluble polymer comprises a net charge under physiological conditions that is selected from the group consisting of negative, neutral and positive.

38. The composition of claim 25, wherein said water-soluble polymer is selected from the group consisting of polyalkylene oxide, polyamide alkylene oxide and derivatives thereof.

39. The composition of claim 25, wherein said water-soluble polymer is a polyamide of the formula

—

[C(O)—

X—

C(O)NH—

Y—

NH]_m—

or —

[NH—

Y—

NH—

C(O)—

X—

C(O)]_m—

,

where X and Y are divalent radicals that may be the same or different and may be branched or linear, and m is an integer from 2 to 100, and where either or both of X and Y comprises a water-soluble repeat unit that may be linear or branched.

40. The composition of claim 39, wherein m is a discrete integer from 2 to 50.

41. The composition of claim 39, wherein said water-soluble repeat unit comprises an ethylene oxide repeat unit of the formula

—

(CH₂—

CH₂—

O)—

or —

(O—

CH₂—

CH₂)—

.

28. A composition comprising a synthetic bioactive protein comprising a polypeptide chain comprising an amino acid sequence of a ribosomally specified glycoprotein, said polypeptide chain having one or more water-soluble polymers attached thereto, wherein said polypeptide chain together with said attached one or more water-soluble polymers has a molecular weight greater than 25 kDa, wherein the composition is uniform with regard to the amino acid attachment sites of the polymer, and wherein the polymer is attached to at least one internal amino acid of the protein, and wherein said synthetic bioactive protein possesses a bioactivity that mimics a bioactivity associated with a cytokine selected from the group consisting of an erythropoiesis stimulating protein, Rantes, and granulocyte colony stimulating factor.

42. A method of treating a human disease or condition that comprises administering to an individual in need of such treatment an effective amount of a pharmaceutical composition comprising a polymer-modified bioactive protein having a monomer polypeptide molecular weight greater than about 25 kDa, wherein the polymer-modified bioactive protein possesses a bioactivity that mimics a bioactivity associated with a natural human protein receptor or fragment thereof, protein receptor ligand or fragment thereof, or a cytokine, wherein the composition is uniform with regard to the attachment sites of the polymer to the protein, and wherein the polymer is attached to at least one internal amino acid of the protein.

43. The method of claim 42, wherein said bioactive protein is a synthetic protein having a bioactivity of a cytokine.

44. The method of claim 43, wherein said cytokine is selected from the group consisting of an interleukin, an erythropoiesis stimulating protein, an interferon, a lymphokine, a chemokine, a growth factor, a colony stimulating factor, and a signal peptide hormone.

45. A method of producing a polymer-modified polypeptide chain of a synthetic bioactive polymer-modified protein, said method comprising

providing peptide segments comprising non-overlapping amino acid sequences of a polypeptide chain of said synthetic bioactive polymer-modified protein, wherein one or more of said peptide segments comprises an irregular amino acid having a first chemoselective functional group attached thereto, and

reacting said irregular amino acid with a water-soluble polymer having a second chemoselective functional group attached thereto, wherein the second chemoselective group is uniquely and mutually reactive with the first chemoselective group, to obtain at least one of said peptide segments having a polymer attached thereto,

chemically ligating said peptide segments to obtain a polymer-modified polypeptide chain of said synthetic bioactive polymer-modified protein.

46. The method of claim 45, wherein said polypeptide chain comprises an amino acid sequence of a ribosomally specified protein.

47. The method of claim 46, wherein said ribosomally specified protein is a mammalian protein.

48. The method of claim 47, wherein said mammalian protein is a cytokine.

49. The method of claim 48, wherein said cytokine is selected from the group consisting of an interleukin, an erythropoiesis stimulating protein, an interferon, a lymphokine, a chemokine, a growth factor, a colony stimulating factor, and a signal peptide hormone.

50. The method of claim 45, which further comprises folding said polymer-modified polypeptide chain whereby a synthetic bioactive polymer-modified protein is produced.

51. The method of claim 45, wherein one or more of said peptide segments are partially protected.

52. The method of claim 45, wherein one or more of said peptide segments are unprotected.

53. The method of claim 45, wherein said chemically ligating comprises a chemoselective ligation chemistry selected from the group consisting of native chemical ligation, extended native chemical ligation and pseudo native chemical ligation.

54. The method of claim 45, wherein said water-soluble polymer comprises a molecular weight of between 1,500 and 80,000 Daltons.

55. A method of producing a polymer-modified polypeptide chain of a synthetic bioactive polymer-modified protein, said method comprising:

a. chemically ligating peptide segments comprising non-overlapping amino acid sequences of said synthetic bioactive polymer-modified protein to form a full length polypeptide chain corresponding to the amino acid sequence of said synthetic bioactive polymer-modified protein, wherein one or more of said peptide segments comprises an irregular amino acid having a first unique chemoselective group attached thereto; and

b. chemically ligating a water-soluble polymer to said full length polypeptide chain, said water-soluble polymer comprising a second chemoselective group that is mutually and uniquely reactive with said first unique chemoselective group, whereby a polymer-modified polypeptide chain of said synthetic bioactive polymer-modified protein is produced.

56. The method of claim 55, which further comprises folding said polymer-modified polypeptide chain whereby a synthetic bioactive polymer-modified protein is produced.

57. A method of producing a synthetic bioactive polymer-modified protein, said method comprising

a. chemically ligating peptide segments comprising non-overlapping amino acid sequences of said synthetic bioactive polymer-modified protein to form a full length polypeptide chain corresponding to the amino acid sequence of said synthetic bioactive polymer-modified protein, wherein one or more of said peptide segments comprises a non-native side chain comprising a first unique chemoselective group that is unreactive with a side chain functional group of an amino acid of a genetically encoded amino acid;

b. folding said full length polypeptide chain to form a folded polypeptide chain; and

c. chemically ligating a water-soluble polymer to said folded polypeptide chain, said water-soluble polymer comprising a second chemoselective group that is mutually and uniquely reactive with said first unique chemoselective group, whereby a polymer-modified polypeptide chain of said synthetic bioactive polymer-modified protein is produced.

58. A molecularly homogeneous water-soluble polymer of the formula:

-U-s1-B-s2-Polymer-s3-J*

wherein;

U is a residue of a unique functional group covalently bonded to a mutually reactive unique functional group of a side chain of an internal amino acid of a peptide,

B comprises a branching core joined to Polymer through amide bonds, and

Y is —

(CH₂—

(CH₂—

CH₂—

O)₃—

CH₂—

CH₂—

CH₂)_z—

or —

(CH₂—

CH₂—

CH₂—

(O—

CH₂—

CH₂)₃—

CH₂)_z, where z is 6 to 36,

Polymer is a polyamide having a molecular weight greater than about 5,000 Da of the formula —

[C(O)—

X—

C(O)—

NH—

Y—

NH]_n—

or —

[NH—

Y—

NH—

C(O)—

X—

C(O)]_n—

, where X and Y are divalent radicals that may be the same or different and may be branched or linear, and n is a discrete integer from 2 to 50, and where either or both of X and Y comprises a substantially non-antigenic water-soluble repeat unit that may be linear or branched,

J* is a residue of a substantially non-antigenic pendant group having a net charge under physiological conditions selected from the group consisting of negative, positive and neutral, and

s1, s2, and s3 are spacer or linker moieties that may be the same or different, and may be individually present or absent.

59. The water-soluble polymer of claim 58, wherein J* comprises an ionizable group that comprises a net negative charge under physiological conditions.

60. The water-soluble polymer of claim 58, wherein X is —

X′

—

NH—

or —

NH—

X′

—

, wherein X′

is a divalent radical comprising a water-soluble repeat unit that may be linear or branched.

61. The water-soluble polymer of claim 58, wherein Y is —

Y′

—

NH—

or —

NH—

Y′

—

, wherein Y′

is divalent radical.

62. The water-soluble polymer of claim 61, wherein Y′

comprises a polyethylene oxide of formula (—

CH₂—

CH₂—

O—

)_z or (O—

CH₂—

CH₂—

)_z where z is 2 to 50.